Mixed Topics
Rare Diseases Report 2022
Myasthenia gravis: Finding strength in treatment options
Although treatment might have once been considered stagnant, newer expert consensus and novel research are generating optimism for innovative...
Opinion
The marked contrast in pandemic outcomes between Japan and the United States
Over time Japan has the least cumulative deaths per capita of any major country in the world.
Livin' on the MDedge
Keep menstrual cramps away the dietary prevention way
Plus: Unemotional robots provoke emotional humans, superorganisms walk and leap around children’s mouths.
Feature
The truth about the ‘happy hormone’: Why we shouldn’t mess with dopamine
Since its first synthesis in the early 20th century, dopamine has often been misunderstood and oversimplified – and it seems the story is...
Latest News
How do patients with chronic urticaria fare during pregnancy?
“Overall, these findings suggest that patients should continue their treatments using an individualized dose to provide optimal symptom control,”...
Livin' on the MDedge
Malaria vaccine gets special delivery by tiny health personnel
Plus: Sleeping and sweating the years away and dragon-sized embezzling from a cancer charity.
Livin' on the MDedge
Meet our newest genetically engineered frenemy, herpes
Plus: Cooking and cleaning your way to air pollution, dying to become a tree, and thawing out “COVID-frozen” goals.
Livin' on the MDedge
Early bird gets the worm, night owl gets the diabetes
Plus: Sweating for mosquito science, sharing genes with zebrafish, and sharing vomit with synanthropic flies.
Commentary
Quiet quitting: Are physicians dying inside bit by bit? Or setting healthy boundaries?
Quiet quitters believe that it is possible to have good boundaries and yet remain productive, engaged, and active within the workplace.
Livin' on the MDedge
‘Dr. Caveman’ had a leg up on amputation
Plus: Walking your way to a quieter baby, lending a nose to Parkinson’s research, and identifying the office flirts.
Latest News
Targeted anti-IgE therapy found safe and effective for chronic urticaria
Two phase 3 trials associated ligelizumab with efficacy comparable to omalizumab, an approved CSU therapy.